Real-World Evidence for Potential Suicidality Risk with Glucagon-Like Peptide-1 Receptor Agonists This project will estimate the incidence of new onset suicidality among adults following initiation of a monotherapy glucagon-like peptide-1 receptor agonist (GLP-1RA) medication and to investigate the risk of…
This study examined atypical antipsychotic prescribing by Food and Drug Administration (FDA) approved-use (on-label) status for adolescents before and during the COVID-19 pandemic. Retrospective data were collected from electronic health records (EHRs) of adolescents aged 10-17 years in Kaiser Permanente…
Division of Research
4480 Hacienda Drive
Pleasanton, CA 94588
Privacy Policy | Terms and Conditions
Follow us on these external social media sites that will open in a new browser window.
© 2024 Kaiser Permanente Division of Research